Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02240030 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety Study of CVT-301 In Parkinson's Disease Patients With OFF Episodes
A Phase 3 study of Idiopathic Parkinson´s Disease, sponsored by Acorda Therapeutics.
- Completed
- Registry status
- Phase 3
- Development phase
- 351
- Enrollment target
- 20
- Study locations
NCT02240030 is a Phase 3 study of Idiopathic Parkinson´s Disease that has completed, run by Acorda Therapeutics. The registered enrollment target is 351 participants, above the 170-participant average among 7 other Idiopathic Parkinson´s Disease trials with a reported enrollment target (106% higher). The trial reports 20 study locations across 4 states.
The verdict
NCT02240030, a Phase 3 study of Idiopathic Parkinson´s Disease, has completed, sponsored by Acorda Therapeutics.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 351 participants
- Enrollment target
- 20
- Study locations
Study Summary
This randomized, multicenter, placebo-controlled, double-blind study will evaluate the efficacy and safety of inhaled CVT 301 compared with placebo in PD patients experiencing motor response fluctuations (OFF phenomena) as an outpatient (i.e., at home) and in the clinic. Patients who successfully complete this study will be eligible to enroll into a 12 month treatment extension (CVT-301-004E) study.
Conditions Studied
Interventions
- OTHER Placebo
- DRUG CVT-301 Low Dose
- DRUG CVT-301 High Dose
Study Locations (20)
California
- Acorda Site #5042 - Fresno
- Acorda Site #5064 - Fullerton
- Acorda Site #5035 - Loma Linda
- Acorda Site #5027 - Long Beach
- Acorda Site #5037 - Los Angeles
- Acorda Site #5070 - Pasadena
- Acorda Site #5047 - Reseda
- Acorda Site #5068 - Santa Ana
- Acorda Site #5069 - Torrance
Florida
- Acorda Site #5046 - Atlantis
- Acorda Site #5053 - Aventura
- Acorda Site #5013 - Boca Raton
- Acorda Site #5016 - Jacksonville
- Acorda Site #5071 - Maitland
- Acorda Site #5044 - Orlando
- Acorda Site #5060 - Palm Beach Gardens
- Acorda Site #5001 - Port Charlotte
- Acorda Site #5065 - St. Petersburg
Arizona
- Acorda Site #5020 - Scottsdale
District of Columbia
- Acorda Site #5052 - Washington D.C.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 351 participants |
| Start Date | 2014-11 |
| Est. Completion | 2016-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02240030
The ClinicalTrials.gov registry entry for NCT02240030 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 351 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 170-participant average among 7 other Idiopathic Parkinson´s Disease trials with a reported enrollment target (106% higher). The listed sponsor is Acorda Therapeutics, which has 36 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Idiopathic Parkinson´s Disease appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT02240030 reports 20 study locations spanning 4 distinct geographic areas - top geographies include California, Florida, Arizona.
Frequently Asked Questions
What is clinical trial NCT02240030 about?
NCT02240030 is a clinical study titled "Efficacy and Safety Study of CVT-301 In Parkinson's Disease Patients With OFF Episodes". This randomized, multicenter, placebo-controlled, double-blind study will evaluate the efficacy and safety of inhaled CVT 301 compared with placebo in PD patients experiencing motor response fluctuations (OFF phenomena) as an outpatient (i.e., at home) and in the clinic. Patients who successfully c...
What is the current status of trial NCT02240030?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 351 participants. The study started on 2014-11. Estimated completion is 2016-12.
What conditions does trial NCT02240030 study?
This clinical trial studies the following conditions: Idiopathic Parkinson´s Disease.
What interventions are being tested in trial NCT02240030?
The interventions under investigation include: Placebo (OTHER), CVT-301 Low Dose (DRUG), CVT-301 High Dose (DRUG).
Who is sponsoring clinical trial NCT02240030?
This trial is sponsored by Acorda Therapeutics, which has 36 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02240030 being conducted?
This trial has 20 study locations across Arizona, California, District of Columbia, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Idiopathic Parkinson´s Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Infusion of Apomorphine: Long-term Safety Study
ACTIVE NOT RECRUITING · Phase 3
-
MOTION, Safinamide in Early IPD, as add-on to Dopamine Agonist
COMPLETED · Phase 3
-
Long Term Study of Istradefylline in Subjects With Moderate to Severe Parkinson's Disease
COMPLETED · Phase 3
-
A Study to Assess Safety and Efficacy of Surgical Implant of RNDP-001 in Patients With Idiopathic Parkinson's Disease
RECRUITING · Phase 1
-
Efficacy and Safety Study of Inhaled CVT 301 in Parkinson's Disease Patients for Treatment of OFF Episodes
COMPLETED · Phase 2
-
Pharmacokinetics and Pharmacodynamics of IPX054 in Subjects With Parkinson's Disease
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.